Supplementary Table S5. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors from Day 1-4 post injection. (n = 4)

Supplementary Figure S13. Autoradiographic images and H&E staining images of subcutaneous CT26 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers. *Indicate the presence of necrosis.

Supplementary Figure S4. Coronal μPET/CT fusion and MIP images obtained at 18 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing 22rv1 subcutaneous tumors over left flanks.

Supplementary Figure S2. Pilot PET/CT studies in prostate, pancreatic, and colorectal cancer models to measure the enhanced permeability retention effect using [89Zr]PEG-DFB1-TLZ3.

Supplementary Table S4. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB4 on different subcutaneous tumors from Day 1-4 post injection. (n = 4)

Supplementary Figure S23. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of 89Zr labeled nanocarriers in nude mice inoculated with 22rv1 cells via intracardiac injection at 72 h postinjection. (n = 4, mean ± SD)

Supplementary Figure S21. Autoradiographic images and H&E staining images of metastatic tumor, and kedney sections from day 1 to day 4 post injection of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule. (NA = Data not available)

Supplementary Table S1. Region of interest analysis data reported as %ID/cc of the [89Zr]PEG-DFB1-TLZ3 on on different subcutaneous tumors on 24 h and 72 h post injection. (n = 4)

Supplementary Table S3. Organ biodistribution data in %ID/Organ tissue for [89Zr]PEG-DFB1-TLZ3 at 72 h in mice model bearing different subcutaneous tumors. (n = 4)

Supplementary Table S14. Comparison of influx and efflux rates of [89Zr]PEG-DFB4 and [89Zr]PEG-DFB1-TLZ3 conjugates in different subcutaneous tumor models (n = 4, mean ± SD). *Prior published data.6

Supplementary Figure S12. Autoradiographic images and H&E staining images of subcutaneous 22rv1 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers. *Indicate the presence of necrosis.

Supplementary Figure S18. BLI of all mice in the cohort inoculated with 22rv1-Luc cells in the left kidney capsule that demonstrate prominent signal of metastatic tumors at the neck and thigh region on the day of [89Zr]PEG-DFB1-TLZ3 injection. Black arrows indicate the presence of metastatic tumors.

Supplementary Figure S7. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-610 patient derived xenograft (PDX) of tumors over left flanks.

Supplementary Figure S1. (a) Zeta potential of the StarPEG conjugates PEG-DFB4 and PEG-DFB1-TLZ3 with an average surface charge of -4.04±0.21 mV and -1.41±0.22 mV, respectively (n = 3). (b) TEM images of PEG-DFB4 and PEG-DFB1-TLZ3 showing the formation of nanoparticles in the range of 10 to 15 nm. TEM samples were prepared by dropcasting the water solution (0.25 mg/mL) of respective StarPEG on carbon coated copper grid of 200 mesh.

Supplementary Figure S14. Autoradiographic images and H&E staining images of PDX LTL-545 tumor sections from day 1 to day 4 post injection of 89Zr labeled nanocarriers.

Supplementary Figure S6. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of 89Zr labeled nanocarriers in nude mice bearing LTL-545 patient derived xenograft (PDX) of tumors over left flanks.

Supplementary Figure S20. Organ biodistribution presented in (left) %ID/g, and (right) %ID/organ of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule at 96 h postinjection. (n = 4, mean ± SD)

Supplementary Figure S3. Ex vivo tumor biodistribution, (a) %ID per gram and (b) %ID per organ of nude mice bearing different tumor models including prostate cancer (22rv1, PC3, DU145), colorectal cancer (CT26), and pancreatic cancer (BxPC3) at 24h and 72 h post-injection of [89Zr]PEG-DFB1-TLZ3. The respective (c) tumor uptakes, (d) tumor to muscle ratio, and (e) tumor to blood ratio of the same mice. (n = 4, mean ± SD) (f) Autoradiographic images of tumor sections from mouse model bearing different preclinical cancer xenograft at 72h post-injection of [89Zr]PEG-DFB1-TLZ3.

Supplementary Figure S19. Coronal μPET/CT fusion and MIP images obtained at 24 h, 48 h, 72 h, and 96 h following administration of 150-170 μCi of [89Zr]PEG-DFB1-TLZ3 in nude mice inoculated with 22rv1 cells in the left kidney capsule (red arrow). Yellow arrows indicate metastatic tumor.

Supplementary Table S8. Organ biodistribution analysis data in %ID/g tissue for 89Zr labeled nanocarriers at 96 h in mice model bearing CT26 subcutaneous tumors. (n = 5)